Switch Study of Existing Atypical Antipsychotics to Bifep... | NCT00347425 | Trialant

Switch Study of Existing Atypical Antipsychotics to Bifep... | NCT00347425 | Trialant

Sponsor/Collaborators Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
A	Other		Drug: Aripiprazole Drug: Olanzapine Drug: Risperidone Drug: Quetiapine Drug: Ziprasidone
B	Other		Drug: Aripiprazole Drug: Olanzapine Drug: Risperidone Drug: Quetiapine Drug: Ziprasidone

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Successful switch defined as those who complete the 4 weeks core study with no worsening of 2 successive post baseline assessments on the CGIS, exacerbation of EPS, or cardiovascular risk factors (body weight and fasting triglycerides) from baseline.		4 weeks

Contacts/Locations Module

Ancestor Terms

ID	Term
D010879	Piperazines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D015363	Quinolones
D011804	Quinolines
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D001569	Benzodiazepines
D001552	Benzazepines
D011744	Pyrimidinones
D011743	Pyrimidines
D003987	Dibenzothiazepines
D013841	Thiazepines
D013846	Thiepins
D013457	Sulfur Compounds
D009930	Organic Chemicals
D006575	Heterocyclic Compounds, 3-Ring